All In Biotech

NDA 021345 · Mylan Ireland LTD

Arixtra

Fondaparinux Sodium · Subcutaneous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2001

Dec 7, 2001

Approved uses

6

Original approval plus efficacy supplements

Registered trials

64

29 Phase 3, 4 recruiting

FAERS reports

8,080

7,120 serious, 1,444 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH), heparinoids, or fondaparinux sodium and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between the administration of fondaparinux sodium and neuraxial procedures...

What it is approved for

From the label in effect Dec 15, 2024.

Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: • Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. ( 1.1 ) • Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin sodium. ( 1.2 , 1.3 ) • Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. ( 1.4 ) 1.1 Prophylaxis of Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (DVT) in adults, which may lead to pulmonary embolism (PE): • in patients undergoing hip fracture surgery, including extended prophylaxis; • in patients undergoing hip replacement surgery; • in patients undergoing knee replacement surgery; • in patients undergoing abdominal surgery who are at risk for thromboembolic complications. 1.2 Treatment of Acute Deep Vein Thrombosis in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis in adults when administered in conjunction with warfarin sodium. 1.3 Treatment of Acute Pulmonary Embolism in Adult Patients Fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism in adults when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. 1.4 Treatment of Venous Thromboembolism in Pediatric Patients Fondaparinux sodium injection is indicated for the treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg .

Mechanism: The antithrombotic activity of fondaparinux sodium is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect fibrinolytic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 2024 Supplement 52 · Efficacy LabelLetter
  • May 26, 2005 Supplement 10 · Efficacy LabelLetter
  • May 28, 2004 Supplement 4 · Efficacy LabelLetter
  • May 28, 2004 Supplement 5 · Efficacy LetterLabel
  • Jun 17, 2003 Supplement 2 · Efficacy · priority review LabelLetter
  • Dec 7, 2001 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewLetterLabel
4 products under this application
  • ARIXTRA · FONDAPARINUX SODIUM 7.5MG/0.6ML (7.5MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
  • ARIXTRA · FONDAPARINUX SODIUM 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
  • ARIXTRA · FONDAPARINUX SODIUM 10MG/0.8ML (10MG/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP
  • ARIXTRA · FONDAPARINUX SODIUM 5MG/0.4ML (5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Fondaparinux" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaemia610
  • haematoma561
  • pulmonary embolism449
  • off label use372
  • haemorrhage353
  • haemoglobin decreased339
  • death297
  • deep vein thrombosis294
  • dyspnoea272
  • thrombocytopenia264
  • drug ineffective259
  • pyrexia240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
200585
2006193
2007510
2008608
2009748
2010772
2011745
2012745
2013676
2014561
2015274
2016187
2017215
2018293
2019203
2020208
2021178
2022172
2023171
2024156
2025145
202697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arixtra (Fondaparinux Sodium)

2024 spending

$211K

Beneficiaries

n/a

46 claims

Per beneficiary

n/a

$181.92 per unit

View as table
YearSpending
2020$632,611
2021$431,028
2022$332,756
2023$219,451
2024$211,072

Part B: Arixtra* (Fondaparinux Sodium*) · HCPCS J1652

2024 spending

$2K

Beneficiaries

28

147 claims

Per beneficiary

$76

2024 ASP limit $1.03 per unit

View as table
YearSpending
2020$10,985
2021$7,531
2022$4,918
2023$2,092
2024$2,130

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 232 on PubMed

Sponsor: Mylan Ireland LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.